Halozyme Therapeutics reported $7.51M in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US USD 41.08M 1.52M
Amgen AMGN:US USD 368M 40M
Baxter International BAX:US USD 109M 16M
Cytokinetics CYTK:US USD 6.8M 4M
Eli Lilly And LLY:US USD 81.5M 300K
Esperion Therapeutics ESPR:US USD 14.15M 113K
Halozyme Therapeutics HALO:US USD 7.51M 4.41M
Immunogen IMGN:US USD 867K 211K
Intercept Pharmaceuticals ICPT:US USD 5.24M 1.43M
Intrexon XON:US USD 2.04M 27K
IONIS PHARMACEUT IONS:US USD 2.14M 9K
JAZZ PHA JAZZ:US USD 83.74M 19.86M
Mannkind MNKD:US USD 5.28M 3.81M
Nektar Therapeutics NKTR:US USD 6.95M 275K
Peregrine Pharmaceuticals PPHM:US USD 518K 37K
Pfizer PFE:US USD 311M 18M
United Therapeutics UTHR:US USD 9.2M 3M